Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Strand Therapeutics is raising $52,143,967.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jacob Becraft played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Strand Therapeutics
Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics. This area was untapped by traditional synthetic biology, which led them to build their own mRNA programming language, creating the worlds first platform for mRNA smart therapies. Strands mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patients body using mRNA-encoded logic circuits. These circuits can implement cell-type specific expression by sensing and classifying the unique miRNA expression signatures of cells, as well as controlling the dosage of protein expression by responding to exogenously administered small molecules.

To learn more about Strand Therapeutics, visit http://www.strandtx.com/

Contact:
Jacob Becraft, Chief Executive Officer
309-360-9875
https://www.linkedin.com/in/jacob-becraft-biotech/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved